Obinutuzumab for Rituximab-Refractory Membranous Nephropathy Secondary to Sjögren Syndrome (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0700; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Additionally, retrospective analyses comparing the efficacy of obinutuzumab versus rituximab as primary therapies in treatment-naïve primary MN have shown comparable or greater remission with obinutuzumab. This case highlights the potential efficacy of obinutuzumab in achieving remission of MN secondary to SS, particularly following relapse with rituximab therapy, supporting its consideration as an alternative therapeutic in refractory cases."
Glomerulonephritis • Immunology • Nephrology • Renal Disease • Sjogren's Syndrome
|
|
Albert I. Yeam; Christopher Z. Liu; Caroline A. Gee; Ramy Magdy Hanna
|